The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy
Open accessAbstract
PURPOSE: Clinicopathologic features and biochemical recurrence are sensitive, but not specific, predictors of metastatic disease and lethal prostate cancer. We hypothesize that a genomic expression signature detected in the primary tumor represents true biological potential of aggressive disease and provides improved prediction of early prostate cancer metastasis. METHODS: A nested case-control design was used to select 639 patients from the Mayo Clinic tumor registry who underwent radical prostatectomy between 1987 and 2001. A genomic classifier (GC) was developed by modeling differential RNA expression using 1.4 million feature high-density expression arrays of men enriched for rising PSA after prostatectomy, including 213 who experienced early clinical metastasis after biochemical recurrence. A training set was used to develop a random forest classifier of 22 markers to predict for cases--men with early clinical metastasis after rising PSA. Performance of GC was compared to prognostic factors such as Gleason score and previous gene expression signatures in a withheld validation set. RESULTS: Expression profiles were generated from 545 unique patient samples, with median follow-up of 16.9 years. GC achieved an area under the receiver operating characteristic curve of 0.75 (0.67-0.83) in validation, outperforming clinical variables and gene signatures. GC was the only significant prognostic factor in multivariable analyses. Within Gleason score groups, cases with high GC scores experienced earlier death from prostate cancer and reduced overall survival. The markers in the classifier were found to be associated with a number of key biological processes in prostate cancer metastatic disease progression. CONCLUSION: A genomic classifier was developed and validated in a large patient cohort enriched with prostate cancer metastasis patients and a rising PSA that went on to experience metastatic disease. This early metastasis prediction model based on genomic expression in the primary tumor may be useful for identification of aggressive prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Breiman, L. (2001) · Machine Learning · doi:10.1023/a:1010933404324 · Cited by 133,538
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
Classification and Regression by randomForest
Liaw, A. I., & Wiener, M. C. (2007) · Cited by 18,594
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Cancer treatment and survivorship statistics, 2012
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., et al. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21149 · Cited by 2,928
HMDB 3.0—The Human Metabolome Database in 2013
Wishart, D. S., Jewison, T., Guo, A. C., Wilson, M., Knox, C., Liu, Y., Djoumbou, Y., Mandal, R., Aziat, F., Dong, E., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1065 · Cited by 2,845
Gene expression correlates of clinical prostate cancer behavior
Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00030-2 · Cited by 2,512
Cited by
Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V., & Madabhushi, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0252-y · Cited by 1,698
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Translating RNA sequencing into clinical diagnostics: opportunities and challenges
Byron, S. A., Van Keuren-Jensen, K. R., Engelthaler, D. M., Carpten, J. D., & Craig, D. W. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.10 · Cited by 809
Seiler, R., Ashab, H. A. D., Erho, N., van Rhijn, B. W. G., Winters, B., Douglas, J., Van Kessel, K. E., Fransen van de Putte, E. E., Sommerlad, M., Wang, N. Q., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.030 · Cited by 786
Self-citationGenetics and biology of prostate cancer
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 750
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer
Chakravarty, D., Sboner, A., Nair, S. S., Giannopoulou, E., Li, R., Hennig, S., Mosquera, J. M., Pauwels, J., Park, K., Kossai, M., et al. (2014) · Nature Communications · doi:10.1038/ncomms6383 · Cited by 621
Self-citationThe bright side of dark matter: lncRNAs in cancer
Evans, J. R., Feng, F. Y., & Chinnaiyan, A. M. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84421 · Cited by 451
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine
He, X., Liu, X., Zuo, F., Shi, H., & Jing, J. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.009 · Cited by 445
Artificial intelligence for clinical oncology
Kann, B. H., Hosny, A., & Aerts, H. J. W. L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.002 · Cited by 370
Copy number alteration burden predicts prostate cancer relapse
Hieronymus, H., Schultz, N., Gopalan, A., Carver, B. S., Chang, M. T., Xiao, Y., Heguy, A., Huberman, K., Bernstein, M., Assel, M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411446111 · Cited by 364
Lalonde, E., Ishkanian, A. S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., Dunning, M. J., Halim, S., Lamb, A. D., Moon, N. C., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71021-6 · Cited by 342
Self-citationKarnes, R. J., Bergstralh, E. J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A. P., Crisan, A., Erho, N., Vergara, I. A., Lam, L. L., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.06.017 · Cited by 325
Self-citationDu, Z., Sun, T., Hacisuleyman, E., Fei, T., Wang, X., Brown, M., Rinn, J. L., Lee, M. G.-S., Chen, Y., Kantoff, P. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms10982 · Cited by 317
Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., Speers, C., Cooperberg, M. R., Kim, W., Ryan, C. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0751 · Cited by 308
Self-citationEpstein, J. I., Amin, M. B., Fine, S. W., Algaba, F., Aron, M., Baydar, D. E., Beltran, A. L., Brimo, F., Cheville, J. C., Colecchia, M., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0015-ra · Cited by 280
Genomic Markers in Prostate Cancer Decision Making
Cucchiara, V., Cooperberg, M. R., Dall’Era, M., Lin, D. W., Montorsi, F., Schalken, J. A., & Evans, C. P. (2018) · European Urology · doi:10.1016/j.eururo.2017.10.036 · Cited by 269
FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
Adams, E. J., Karthaus, W. R., Hoover, E., Liu, D., Gruet, A., Zhang, Z., Cho, H., DiLoreto, R., Chhangawala, S., Liu, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1318-9 · Cited by 269
Self-citationPrensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 264
Self-citationPhenotype prediction from single-cell RNA-seq data using attention-based neural networks
Mao, Y., Lin, Y.-Y., Wong, N. K. Y., Volik, S., Sar, F., Collins, C., & Ester, M. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae067 · Cited by 31
“Oncotype Dx genomic prostate score (Cullen et al. 2015) and Decipher Biopsy score (Erho et al. 2013) also identify gene signatures to predict the risk of metastasis as the tumor outcome.”
BackgroundKarnes, R. J., Sharma, V., Choeurng, V., Ashab, H. A.-D., Erho, N., Alshalalfa, M., Trock, B., Ross, A., Yousefi, K., Tsai, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2745 · Cited by 30
Self-citationEmerging proteomics biomarkers and prostate cancer burden in Africa
Adeola, H. A., Blackburn, J. M., Rebbeck, T. R., & Zerbini, L. F. (2017) · Oncotarget · doi:10.18632/oncotarget.16568 · Cited by 26
Genomic classifiers and prognosis of localized prostate cancer: a systematic review
Boyer, M. J., Carpenter, D. J., Gingrich, J. R., Raman, S. R., Sirohi, D., Tabriz, A. A., Rompre-Broduer, A., Lunyera, J., Basher, F., Bitting, R. L., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00766-z · Cited by 22
Rye, M. B., Bertilsson, H., Andersen, M. K., Rise, K., Bathen, T. F., Drabløs, F., & Tessem, M.-B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4373-y · Cited by 21
Deep Genomic Signature for early metastasis prediction in prostate cancer
Sharifi-Noghabi, H., Liu, Y., Erho, N., Shrestha, R., Alshalalfa, M., Davicioni, E., Collins, C. C., & Ester, M. (2018) · doi:10.1101/276055 · Cited by 11
“2.6 Clinical and Biological Evaluation We evaluate performance of DGS against five competitor methods: (Cuzick et al., 2011), (Penney et al., 2011), (Erho et al., 2013), (Mo et al., 2017), and (Tyekucheva et al., 2017).”
BackgroundMethodSelf-citationPrognostic Genomic Tissue-Based Biomarkers in the Treatment of Localized Prostate Cancer
Ingrosso, G., Alì, E., Marani, S., Saldi, S., Bellavita, R., & Aristei, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010065 · Cited by 9
Metadata
- Authors
- Erho, N., Crisan, A., Vergara, I. A., Mitra, A. P., Ghadessi, M., Buerki, C., Bergstralh, E. J., Kollmeyer, T., Fink, S., Haddad, Z., Zimmermann, B., Sierocinski, T., Ballman, K. V., Triche, T. J., Black, P. C., Karnes, R. J., Klee, G., Davicioni, E., & Jenkins, R. B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-06-24
- Volume
- 8
- Issue
- 6
- Pages
- e66855
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W1998343146
- Cited by
- 644
- References
- 67
- FWCI
- 31.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.